<<

. 2
( 2 .)



iinou aoaeeioaiaea niinianoaiaaee oi?ioae eiiiea- 16. elin A, Murrey FE. Aceclofenac: side effects and safety. Eur J Rheumatol Inflamm
1996; 16: 13–6
aioiinoe (94% iaoeaioia ?aaoey?ii i?eieiaee ?aei-
17. Zabala Gamarra M. Efficacy and tolerability of aceclofenac in a 3–month open trial in
iaiaoaio? aico aoaeeioaiaea).
the treatment of gonarthrosis. Dolor Inflamacion 1993; 1: 3–7.
Eoae, aoaeeioaiae (Ay?oae) yaeyaony IIAI, eioi- 18. Huskisson E, Irani M, Murray F. A large prospective open–label, multicentre SAMM
?ue ii naiae yooaeoeaiinoe ia onooiaao noaiaa?oiui study, comparing the safety of aceclofenac in patients with rheumatic disease. Eur J
eaea?noaaiiui n?aanoaai yoiai eeanna. A oi ?a a?aiy Rheumatol Inflamm 2000; 7: 1–7.
19. Peris F., Bird HA, Serni U et al. Treatment compliance and safety of aceclofenac ver-
ii iaeaaaao oi?ioae ia?aiineiinou?, a ?anoiinoe, ?a-
sus NSAIDs in patients with common arthritis disorders: a meta–analysis. Eur J
eoai?ii–eeoa?iie. ?enei ia?aeaoaeuiuo yaeaiee i?e
Rheumatol Inflamm 1996; 16: 37–45.
aeeoaeuiii aai i?eaia ainoiaa?ii iaiuoa, ?ai i?e ea- 20. Laporte J–R, Ibanez L, Vidal i et al. Upper gastrointestinal bleedng accociated with
?aiee a?oaeie IIAI, aee??ay e naeaeoeaiua eiaeaeoi- the use NSAIDs. Newer versus older agents. Drug Safety 2004; 27 (6): 411–20.
?u oeeeiieneaaiacu–2. Aoaeeioaiae ia ieacuaaao ia- 21. Lemmel E–M, Leeb B, De Bast J, Aslanidis S. Patient and Physician Satisfaction with
Aceclofenac: Results of the European Observational Cohort Study (E?perience with
aaoeaiiai aeeyiey ia iaoaaieeci aeaeeiiaiai o?yua o
Aceclofenac for Inflammatory Pain in Daily Practice). Curr Med Research Opin 2002; 18
aieuiuo inoaia?o?icii. Iai?ioea, ii iaeaaaao oiia?i-
(3): 146–53.
i?ioaeoeaiie aeoeaiinou?, oae eae niinianoaoao iiau-
oaie? neioaca i?ioaiaeeeaiia oiia?ioeoaie aeaeeii-
aiai o?yua. Ana auoaneacaiiia iicaieyao ?anniao?e-
aaou aoaeeioaiae eae i?aia?ao auai?a a ea?aiee in-
oaia?o?ica.



Oaaeeoa 2. Iniiaiua ?aeoai?ii–eeoa?iua
ia?aeaoaeuiua yaeaiey ii ?acoeuoaoai
SUMM enneaaiaaiey [17]
(%)


Aeniainey 5,4 6,7 0,017
Aaaiieiaeuiay aieu 2,5 4,4 <0,001
Aea?ay 1,5 3,6 <0,001
Oioiioa 1,6 2,4 0,01


395

13, 7, 2005

<<

. 2
( 2 .)